EGFR and lung cancer: This path of personalized medicine, using drugs targeting epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, has been shown to be successful by increasing the survival of patients with lung cancer [3].